Letters Prostate cancer screening

Report bias favours screening

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d3703 (Published 14 June 2011) Cite this as: BMJ 2011;342:d3703
  1. Maren Dreier, senior researcher in epidemiology1,
  2. Thorsten Meyer, professor in rehabilitation research1,
  3. Ulla Walter, professor in public health1
  1. 1Hanover Medical School (MHH), Institute for Epidemiology, Social Medicine and Health Systems Research, 30625 Hanover, Germany
  1. dreier.maren{at}mh-hannover.de

While aiming to assess prostate cancer specific mortality, Sandblom and colleagues indicate a “prostate cancer specific mortality” in the screening group of 35% and in the control group of 45%, which actually is the case fatality rate.1 The true prostate cancer specific mortality was 2% (30/1494) in the screening group and 1.7% (130/7532) in …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe